3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.
3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79-130+ months after 3F8 treatment without additional systemic therapy and no delayed neurological complications. The potential benefits of 3F8 when added to chemoradio-therapy warrant further investigation.
Cheung
N K
NK
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Kushner
B H
BH
Yeh
S D
SD
Larson
S M
SM
D015746:Abdominal Pain / Q000139:chemically induced; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005334:Fever / Q000139:chemically induced; D005732:Gangliosides / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D007167:Immunotherapy; D007223:Infant; D007231:Infant, Newborn; D009447:Neuroblastoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D012120:Respiration Disorders / Q000139:chemically induced; D016896:Treatment Outcome; D014581:Urticaria / Q000139:chemically induced
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D005732:Gangliosides; C019403:ganglioside, GD2